Darzalex Faspro 1800 mg/15mL
daratumumab and hyaluronidase-fihj (human recombinant) · INJECTION · Janssen Biotech, Inc.
Darzalex Faspro is a injection containing daratumumab and hyaluronidase-fihj (human recombinant) at 1800 mg/15mL, taken subcutaneous. Manufactured by Janssen Biotech, Inc..
Key Facts
- Brand Name
- Darzalex Faspro
- Generic Name
- daratumumab and hyaluronidase-fihj (human recombinant)
- NDC Code (Product)
57894-503- Manufacturer
- Janssen Biotech, Inc.
- Strength
- 1800 mg/15mL
- Dosage Form
- INJECTION
- Route
- SUBCUTANEOUS
- Marketing Status
- Application #
- BLA761145
- Drug Class
- CD38-directed Cytolytic Antibody [EPC]; Endoglycosidase [EPC]
- Marketing Start
- 05/01/2020
Recall History
No Recall HistoryFrequently Asked Questions
What is Darzalex Faspro used for?
Darzalex Faspro contains daratumumab and hyaluronidase-fihj (human recombinant). It is a injection taken subcutaneous. Consult your doctor for specific uses.
Is Darzalex Faspro a controlled substance?
Darzalex Faspro is not classified as a controlled substance by the DEA.
What is the generic name for Darzalex Faspro?
The generic name for Darzalex Faspro is daratumumab and hyaluronidase-fihj (human recombinant). There are no other listed brand versions of daratumumab and hyaluronidase-fihj (human recombinant).
What is the NDC code for Darzalex Faspro 1800 mg/15mL?
The NDC (National Drug Code) for Darzalex Faspro 1800 mg/15mL is 57894-503, listed by Janssen Biotech, Inc..
Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.
Data from openFDA · Public domain (CC0 1.0)